Compare SIDU & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIDU | PLX |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.7M | 230.0M |
| IPO Year | 2021 | 1996 |
| Metric | SIDU | PLX |
|---|---|---|
| Price | $1.92 | $2.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 4.7M | 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,672,646.00 | ★ $53,399,000.00 |
| Revenue This Year | N/A | $9.67 |
| Revenue Next Year | $100.00 | $23.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $1.34 |
| 52 Week High | $5.39 | $3.19 |
| Indicator | SIDU | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 40.63 | 44.14 |
| Support Level | $1.02 | $1.39 |
| Resistance Level | $2.19 | $2.66 |
| Average True Range (ATR) | 0.19 | 0.15 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 22.55 | 4.96 |
Sidus Space Inc is a Space and Defense as-a-Service company focused on providing complex space hardware, satellite/spacecraft design, manufacture, launch, and data solutions for both government and commercial in-space missions for all destinations through the solar system. This includes a Space-based infrastructure of multi-mission satellites with hyperspectral, multi-spectral, and other sensors to provide monitoring services and solutions to multiple sectors and industries. The company supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers.
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.